P/E ratio for Rohto Pharmaceutical (4527.T)
P/E ratio as of March 2025 (TTM): 17.0
According to Rohto Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 16.96. At the end of 2022 the company had a P/E ratio of 21.1.
P/E ratio history for Rohto Pharmaceutical from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 21.1 | 26.65% |
| 2021 | 16.7 | -36.58% |
| 2020 | 26.3 | -19.69% |
| 2019 | 32.7 | -5.22% |
| 2018 | 34.5 | 18.11% |
| 2017 | 29.2 | 45.08% |
| 2016 | 20.2 | -22.41% |
| 2015 | 26.0 | 8.89% |
| 2014 | 23.9 | 22.11% |
| 2013 | 19.5 | 42.07% |
| 2012 | 13.8 | -3.46% |
| 2011 | 14.2 | 6.12% |
| 2010 | 13.4 | -25.81% |
| 2009 | 18.1 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.